Cancer-related cognitive impairment (CRCI) is a frequent side effect experienced by an
increasing number of cancer survivors with a significant impact on their quality of life …

Cancer-related cognitive impairment (CRCI) is commonly experienced by individuals with
non-central nervous system cancers throughout the disease and treatment trajectory. CRCI …

Alloreactive and autoimmune responses after allogeneic hematopoietic cell transplantation
can occur in nonclassical chronic graft-versus-host disease (chronic GVHD) tissues and …

Cognitive dysfunction is a challenging adverse effect of chemotherapy and radiotherapy that
has limited treatment options. Clinical trials for proposed pharmacotherapeutic interventions …

Acute graft-versus-host disease (GVHD) continues to be a major cause of morbidity and
mortality after allogeneic hematopoietic cell transplant (HCT) in pediatric patients (ie …

Haematopoietic stem-cell transplantation (HSCT) has seen substantial growth among older
adults. Chronological age is no longer viewed as an absolute barrier to HSCT, and …

Background Using the large nationwide French, national, multicenter, prospective cancer
and toxicities (CANTO) cohort, we assessed cognitive functioning change after cancer …

Cancer‐related cognitive impairment (CRCI) is commonly reported post‐chemotherapy in
adults with solid tumours. Hodgkin lymphoma (HL) mostly affects young adults. Data …

Hematopoietic cell transplant (HCT) is an important aspect of treatment for many
hematologic malignancies. As cancer is a disease associated with aging, and hematologic …

Cancer treatment is associated with long lasting cognitive impairment in cancer survivors.
This cognitive impairment is often termed cancer related cognitive impairment (CRCI) …